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The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced
squamous cell carcinoma of the head and neck (SCCHN). Patients receiving definitive treatments were randomly assigned to either
arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week
administration followed by 2-week rest for 6 months. Planned treatment was given in 40% of patients in arm A and 29% in arm B. The
cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.1–69.7%) in arm A and 34.3% (95%
CI: 21.1–47.4%) in arm B, respectively (P¼0.054). Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients
(94.1%) in arm B (P¼0.060). The incidences of diarrhoea (10 vs 28%; Po0.05) and skin toxicities (18 vs 37%; Po0.05) were
significantly higher in arm B. One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI: 70.0–92.4%); arm B 77.0%
(95% CI: 65.0–89.0%). The schedule of 2-week administration followed by 1-week rest seems to be more feasible for oral 6-month
administration of S-1 in adjuvant chemotherapy of locoregionally advanced SCCHN.
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Squamous cell carcinoma of the head and neck (SCCHN) is a
major public health problem because of the poor outcome (Landis
et al, 1999). Two-thirds of patients present with locally advanced
lesions (T3 or T4) and/or regional lymph node involvement (N1–
N3). Recently, many studies on locoregionally advanced SCCHN
have been focusing on neoadjuvant chemotherapy (NAC) with a
high complete response (CR) rate followed by definitive radio-
therapy, or concurrent chemoradiotherapy showing to improve the
survival rate and to preserve functions and organs (Pignon et al,
2000; Monnerat et al, 2002; Forastiere et al, 2003; Haddad et al,
2003). However, 20–30% of advanced patients with a pathologi-
cally CR even after the recent aggressive treatment has been
showing locoregionally recurrent and/or distant metastatic
tumours (unpublished data in our institutes) resulting in the poor
outcome nevertheless (Argiris et al, 2004; Brockstein et al, 2004;
Cohen et al, 2004). Based on these results, more advanced
multidisciplinary treatments should be indispensable in the aim
of improving the poor outcome of patients with advanced SCCHN.
Adjuvant chemotherapy might be a one of the candidates. Several
randomised trials of adjuvant (maintenance) chemotherapy in
advanced SCCHN have been done (Ervin et al, 1987; Jacobs and
Makuch, 1990; Laramore et al, 1992; Johnson et al, 1996). A few
randomised trials regarding adjuvant chemotherapy reported the
possibility of survival benefits (Ervin et al, 1987; Johnson et al,
1996). Instead of intravenous administration of cisplatin (CDDP)
and/or other agents, oral anticancer drugs are attractive for
outpatient use as adjuvant chemotherapy. The fluoropyrimidine
anticancer agent 5-fluorouracil (5-FU) is active in a variety of solid
tumours, particularly gastric, colorectal and SCCHN. Recently, the
adjuvant chemotherapy of UFT (tegafur and uracil in a 1:4 molar
concentration), one of the oral 5-FU agents, has shown a
significant survival benefit in a wide range of carcinomas (Akasu
et al, 2004; Kato et al, 2004; Kinoshita et al, 2005; Noguchi et al,
2005). Furthermore, a prospective randomized trial to evaluate the
efficacy of adjuvant chemotherapy in SCCHN from 67 institutions
in Japan showed the 1-year administration of UFT (300mgday
 1)
in cases receiving curative surgical treatment was clarified to
prevent distant metastasis significantly with a small survival
benefit compared to the outcome of the control cases receiving
curative surgery without adjuvant chemotherapy of UFT (Tsukuda
et al, 1994).
S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is a
dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoro-
pyrimidine (DIF), which showed the highest response rate among
many oral anticancer agents against unresectable advanced
carcinomas in phase II studies (Schoffski, 2004). S-1 is an oral
anticancer agent comprised of tegafur, 5-chloro-2, 4-dihydroxy-
pyridine, and potassium oxonate, in a molar ratio of 1:0.4:1
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s(Shirasaka et al, 1996a,b; Schoffski, 2004). Tegafur is a prodrug of
5-FU and 5-Chloro-2, 4-dihydroxypyridine enhances the serum 5-
FU concentration by the competitive inhibition of DPD, an enzyme
responsible for 5-FU catabolism. Potassium oxonate, a reversible
competitive inhibitor of orotate phosphoribosyl transferase,
inhibits phosphorylation of 5-FU in the gastrointestinal tissue,
reducing the diarrhoea associated with 5-FU.
In a phase II trial of advanced and recurrent SCCHN (59 eligible
cases), S-1 showed a high response rate of 28.8% with acceptable
toxicities (Inuyama et al, 2001). S-1 also showed a higher response
in gastric cancer (Sakata et al, 1998; Koizumi et al, 2000),
colorectal cancer (Ohtsu et al, 2000), biliary tract cancer (Ueno
et al, 2004) and so on. In these studies, S-1 was orally administered
for 4 weeks followed by a 2-week rest period. Main adverse events
were haematological, for example, anemia, leukopenia and
neutropenia,, gastrointestinal, for example, anorexia, diarrhoea
and nausea, and skin toxicities (Schoffski, 2004). To decrease the
toxicity of S-1 without decreasing efficacy and since the median
time to the worst toxic events was 22 days for haematological
toxicities and 15 days for diarrhoea and stomatitis in the above
schedule in advanced gastric cancer (Nagashima et al, 2005), we
devised the schedule of S-1 for 2-week administration followed by
1-week rest is for adjuvant treatment of patients with locoregion-
ally advanced SCCHN and compared the feasibility of its
application with conventional 4-week administration followed by
2-week rest.
MATERIALS AND METHODS
Patients
The following eligibility criteria were used: histologically or
cytologically confirmed SCCHN, stage III or IV curable disease
with no evidence of distant metastases, a primary tumour in the
nasopharynx, mesopharynx, hypopharynx, larynx, oral cavity or
maxillary sinus, age of 20–74 years, Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0, 1 or 2, a WBC count
of 4000mm
 3 or more, an absolute neutrophil count (ANC) of
2000mm
 3 or more, a platelet count of 100000mm
3 or more, a
haemoglobin level of 9.5gdl
 1 or more, AST, ALT and alkaline
phosphatase levels below 2.5 times the upper limit of normal
(ULN), total bilirubin and creatinine levels below than 1.5 times
ULN, a BUN level below the ULN and a 24-h creatinine clearance
rate of more than 60mlmin
 1. The exclusion criteria were patients
with previous chemotherapy, radiotherapy or surgery, concomi-
tant malignancy, significant cardiac arrhythmia or heart failure.
In the 4 weeks after the completion of definitive treatments, no
clinical evidence of locoregional tumours or distant metastasis
were confirmed and adequate organ functions, sufficient oral
intake in particular, were evaluated. All patients provided written
informed consent prior to enrollment in the study and the protocol
was approved by the institutional ethics committee of each
participating institution. On entry to the study, the eligibility of
patients was checked once more via facsimile by the central
administration office (Tokyo).
Treatment schedule
The randomization was performed centrally at the Division of
Environmental and Occupational Health, Toho University School
of Medicine, Tokyo. S-1 was administered orally after meals. The
dosage of S-1 was selected as follows: in a patient with body surface
area (BSA)o1.25m
2, 40mg twice a day (80mgday
 1); BSA of
1.25m
2 but o1.5m
2, 50mg twice a day (100mgday
 1); and
BSAX1.5m
2, 60mg twice a day (120mgday
 1).
Patients receiving definitive treatments were randomly assigned
to either arm A, S-1 administration for 2 weeks followed by a
1-week rest or arm B, S-1 administration for 4 weeks followed by a
2-week rest. In both treatment arms, the administration of S-1 was
continued for 6 months (eight courses in arm A and four courses
in arm B) unless there was any evidence of recurrence, other
malignancies or severe adverse events. The planned total admin-
istration days of S-1 was 112 days in both arms and the planned
total administration doses of S-1 were also identical in both arms.
During the study, the dosage of S-1 was adjusted according to
the degree of haematological and nonhaematological toxicities.
The dosage was planned to be reduced by one level (20mg per day)
in patients with evidence of grade 3 haematological toxicity, or
grade 2 or more nonhaematological toxicity. If recovery from such
toxicities was confirmed at a reduced dose, the administration at
the reduced dosage was continued. If a patient with BSAo1.25m
2
experienced the above toxicities, then no further treatment with S-
1 was done. Patients were observed for at least 1 year after
initiation of S-1 administration.
Evaluation of feasibility and toxicity
All eligible patients who had received any definitive treatment were
considered assessable for feasibility and toxicity. Feasibility was
evaluated by the total administration days and the relative total
administration dose of S-1. The number of patients was calculated
at the time when S-1 administration was stopped or the planned
administration dose per day was reduced because of adverse events
of S-1. The total administration days of S-1 (the planned total
administration days of S-1, 112 days) was evaluated by the
cumulative rate of patients. The relative total administration dose
was expressed by the rate between the actual total administration
dose and the planned total administration dose, and the
cumulative rate of the relative total administration dose was
evaluated in each arm. Patients in whom administration of S-1 was
halted due to tumour recurrence or other non-S-1-related
complications were treated as censored cases. Complete blood
count and blood chemistry studies were performed weekly.
Adverse events were graded according to the National Cancer
Institute-Common Toxicity Criteria (NCI-CTC) version 2.0.
Statistical analysis
Patient characteristics, feasibility, adverse events, disease-free
survival and recurrent sites were analysed. The cumulative total
administration days, the cumulative relative total administration
dose and the 1-year disease-free survival were examined by the
Kaplan–Meier method and the difference in the two arms was
calculated by the log-rank test. The differences in the mean total
administration days and the mean relative total administration
dose between the two arms were compared with Student’s t-test.
The differences in adverse events were evaluated by the w
2 test. The
data were considered to be significant when the P-value was
p0.05.
RESULTS
Patient characteristics
From April 2002 to December 2003, 102 patients with stage III and
IV SCCHN who had received definitive treatments were enrolled
and randomized (51 cases in arm A and 51 in arm B) and all
patients were eligible. One patient in arm A refused the present
study and did not receive chemotherapy or other treatment. The
each number of patients (intention-to-treat population) studied
was 50 cases in arm A and 51 in arm B.
The patient characteristics showed no statistically significant
difference (Table 1). In total, 84% of patients in arm A and 74.5%
in arm B had a PS of 0. In total, 68% of patients in arm A and
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s68.5% in arm B had Stage IVA. The primary therapy had mainly
been surgery or concurrent chemoradiation in both arms.
Feasibility
In total, 40% of patients in arm A receive S-1 administration along
the planned schedule and dose, while 29% in arm B did (not
significant: NS) (Table 2). The rates of cases that discontinued S-1
administration due to adverse events were 22.0% in arm A and
29.4% in arm B, respectively (Table 2). The cumulative rates of
total administration days of S-1 on day 112 were 69.4% (95% CI:
56.0–82.9%) in arm A and 54.4% (95% CI: 40.6–68.1%) in arm B,
respectively (NS, P¼0.147) (Figure 1). The mean of total
administration days in each arm was almost identical (87.3 days
vs 87.2 days) (Table 3). The cumulative rates of the relative total
administration dose at 100% were 54.9% (95% CI: 40.1–69.7%) in
arm A and 34.3% (95% CI: 21.1–47.4%) in arm B, respectively
(P¼0.054) (Figure 2). The mean of the relative total administra-
tion dose in each arm was similar (76.1 vs 75.7%) (Table 3).
Adverse events
Drug-related adverse events are listed in Table 4. Main adverse
events were haematological, gastrointestinal and cutaneous
symptoms. There was no grade 4 adverse event in either arm.
Adverse events were recorded for 41 patients (82.0%) in arm A and
48 patients (94.1%) in arm B (NS, P¼0.060) and the severe adverse
Grade 3 events were observed in seven patients in arm A and in 14
in arm B (NS). In total, 11 patients (22.0%) in arm A and 15
patients (29.4%) in arm B discontinued S-1 administration because
of adverse events induced by the agent (NS).
Stomatitis was observed in six cases of arm A and in four of arm
B. Diarrhoea, which was one of dose limiting toxicities in the S-1
studies in Western countries, was found in five patients (10.0%) of
arm A and in 14 (27.4%) of arm B. Only one in arm A and two in
arm B had grade 3 diarrhoea. In the arm A patient, grade 3
diarrhoea appeared after the completion of three courses and
further administration of S-1 was stopped. In one arm B patient,
Table 1 Patient characteristics
Arm A (n¼50) Arm B (n¼51)
Characteristics No. % No. %
Gender
Male 44 88 48 94.1
Female 6 12 3 5.9
Age (years)
Median 55.5 60.0
(Range) (25–73) (35–74)
PS
0 42 84 38 74.5
1 7 14 12 23.5
2 2 4 1 2.0
Primary sites
Maxillary sinus 5 10 6 11.8
Oral cavity 8 16 14 27.5
Oropharynx 2 4 1 2.0
Nasopharynx 14 28 8 15.7
Hypopharynx 11 22 16 31.4
Larynx 10 20 6 11.8
Stage
III 14 28 13 25.5
IV-A 34 68 35 68.6
IV-B 2 4 3 5.9
Primary therapy
Surgery 22 44 24 47.1
Radiotherapy alone 5 10 4 7.8
Concurrent chemoradiation 23 46 23 45.1
Table 2 Administration of S-1
Arm A (n¼50) Arm B (n¼51)
No. % No. %
Patients following planned schedule
and dose
20 40.0 15 29.4
Patients in whom administration
was halted due to adverse events
11 22.0 15 29.4
Patients with dose-reduction 7 14.0 6 11.8
Patients with delayed courses 14 28.0 19 37.3
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Figure 1 Cumulative rate of total administration days of S-1 in each arm
by Kaplan–Meier method; total administration days of S-1 within a 112-day
administration period were 69.4% (95% CI: 56.0–82.9%) in arm A and
54.4% (95% CI: 40.6–68.1%) in arm B, respectively.
Table 3 Feasibility of S-1
Arm A (n¼50) Arm B (n¼51)
Cumulative rate of total administration
days of S-1 on 112-day (95% CI) 69.4% (56.0–82.9%) 54.4% (40.6–68.1%)
Total administration days
Mean 87.3 days 87.2 days
Standard deviation 37.3 days 35.7 days
Cumulative rate of the relative total
administration dose of S-1 at 100%
(95% CI)
54.9% (40.1–69.7%) 34.3% (21.1–47.4%)
Relative total administration dose
Mean 76.1% 75.7%
Standard deviation 33.2% 31.3%
Feasible adjuvant therapy administration of S-1 for SCCHN
M Tsukuda et al
886
British Journal of Cancer (2005) 93(8), 884–889 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdiarrhoea was observed during the first course and the adminis-
tration was stopped for 7 days. Then the reduced dose of S-1,
according to the administration schedule, was begun and
continued. The other arm B patient with grade 3 diarrhoea had a
3-day rest during the second course and then continued to receive
the same dose without reduction, according to the planned
schedule.
In the adverse events induced by the S-1 administration,
incidences of diarrhoea (10 vs 28%; Po0.05) and skin toxicities,
that is, rash and pigmentation, (18 vs 37%; Po0.05) were
significantly higher in arm B than in arm A. No patient showed
hand-foot syndrome.
Disease-free survival and recurrence
The median follow-up time was 14.7. months (range 12.0–26.2
months). The 1-year disease-free survival rates were 81.2% (95%
CI; 70.0–92.4%) in arm A and 77.0% (95% CI; 65.0–89.0%) in arm
B, respectively (Figure 3). There was no statistically significant
difference in the 1-year disease-free survival in favour of arm A.
In total, 10 patients (20.0%) in arm A and 14 patients (27.5%) in
arm B relapsed. Locoregional recurrence was predominant in both
arms nine of 10 relapsed patients in arm A and 13 of 14 in arm B.
In terms of the site of distant metastasis, there were three cases in
arm A, that is, bone (one case) and lung (2 cases), while five cases
in arm B showed distant metastases in the lung (3), liver (1) and
mediastinum (1).
DISCUSSION
Recently the Radiation Therapy Oncology Group reported post-
operative concurrent radiotherapy and chemotherapy for high-risk
SCCHN improved the local and regional control, and disease-free
survival (Cooper et al, 2004). Adjuvant chemotherapy can also
potentially improve the outcome. The regimen of adjuvant
chemotherapy in randomized studies consisted of three courses
of intravenous low-dose CDDP-based regimen every 6 weeks
(Ervin et al, 1987), monthly intravenous CDDP (80mgm
 2) alone
for 6 months (Jacobs and Makuch, 1990), three courses of
intravenous CDDP (100mgm
 2) with 5-day continuous infusion
of 5-FU at 1000mgm
 2day
 1 (Laramore et al, 1992) and 18
courses of intravenous methotrexate (250mgm
 2) followed by 5-
FU (600mgm
 2) with leucovorin rescue over 6 months on an
outpatient basis (Johnson et al, 1996). A few studies suggested
survival benefits (Ervin et al, 1987; Johnson et al, 1996) and a
decrease in the incidence of distant metastases with adjuvant
chemotherapy (Jacobs and Makuch, 1990; Laramore et al, 1992).
The Head and Neck Contracts Study group showed that adjuvant
chemotherapy, while reducing distant metastases, does not
improve survival significantly in the total of cases studied;
however, a significant survival advantage with adjuvant che-
motherapy was detected for oral cavity cancer and for N2 disease
using a subset analysis (Jacobs and Makuch, 1990). Based on these
results, the group concluded there may be particular sites and
stages for which adjuvant chemotherapy would be advantageous,
since head and neck cancer patients are a heterogeneous group. On
the other hand, one reason why adjuvant chemotherapy for
SCCHN with no clinically residual tumours after definitive
treatments had no impact on survival benefit has been suggested
to be the lack of antitumour effect of the adjuvant chemotherapy
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Figure 2 Cumulative rate of relative total administration dose of S-1 in
each arm by Kaplan–Meier method; relative total administration dose of S-
1 at 100% were 54.9% (95% CI: 40.1–69.7%) in arm A and 34.3% (95% CI:
21.1–47.4%) in arm B (Po0.1), respectively.
Table 4 Drug-related adverse events
Arm A (n¼50) Arm B (n¼51)
G1/2 G3 G1/2 G3
No. (%) No. (%) No. (%) No. (%)
Leukopenia 17 (34) 3 (6) 20 (39) 3 (6)
Neutropenia 12 (24) 11 (22) 4 (8)
Thrombocytepenia 9 (18) 9 (18)
Anaemia 13 (26) 17 (33) 1 (2)
Elevation of Bilirubin 7 (14) 7 (14) 2 (4)
Elevation of ALT, AST 7 (14) 8 (16) 1 (2)
Anorexia 14 (28) 14 (27)
Nausea and vomiting 7 (14) 15 (29)
Diarrhoea 4 (8) 1 (2) 12 (24) 2 (4)
Stomatitis 6 (12) 3 (6) 1 (2)
Other GI toxicity 3 (6) 2 (4)
Cutaneous symptoms 9 (18) 19 (37)
Peripheral neuropathy 1 (2) 2 (4)
Dizziness 2 (4) 1 (2) 2 (4)
General fatigue 10 (20) 6 (12)
Others 8 (16) 2 (4)
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Figure 3 Disease-free survival rate in each arm; 1-year disease-free
survival rates were 81.2% (95% CI: 70.0–92.4%) in arm A and 77.0% (95%
CI: 65.0–89.0%) in arm B, respectively.
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sregimen or the shortage of the duration of adjuvant chemotherapy,
or both.
Adjuvant chemotherapy with oral chemotherapeutic agents has
not been studied in Western countries for HNSCC. Oral
administration of UFT (tegafur and uracil in a 1:4 molar
concentration) has been shown significant survival benefit in the
adjuvant setting in a variety of carcinomas, for example, colorectal,
gastric, lung and breast cancer (Akasu et al, 2004; Kato et al, 2004;
Kinoshita et al, 2005; Noguchi et al, 2005), while 1-year
administration of UFT (300mgday
 1) as adjuvant chemotherapy
for SCCHN after curative surgical treatment significantly pre-
vented distant metastasis with a small survival benefit (Tsukuda
et al, 1994).
Since S-1 is considered to be a more effective drug than UFT,
long-term S-1 administration could be a candidate for adjuvant
chemotherapy of SCCHN. However, because S-1 is more toxic than
UFT and also the influence of prior therapy must not be ignored in
adjuvant chemotherapy, we wondered if the standard schedule of
S-1 could be adjusted for long-term administration. In fact, the
rate of adverse reactions in gastric cancer patients receiving S-1
adjuvant chemotherapy was higher than in phase II studies
(Kinoshita et al, 2004).
From the viewpoint of the long-term administration for over 6
months in the adjuvant chemotherapy setting, we considered that a
treatment schedule of 2-week administration followed by a 1-week
rest might be more feasible and safer with the same antitumour
effects as those with the conventional 4-week administration
followed by 2-week rest, since the dose intensity is identical, but
the rest time is spread out in the former method. Furthermore, the
results of phase I and II trials using combined CDDP with S-1, that
is, administration of S-1 at 40, 50 or 60mgm
 2 twice a day for 14
consecutive days and CDDP at 60 or 70mgm
 2 on the mid-day of
S-1 administration (Fujii et al, 2005) encouraged us to conducted
the current feasibility study of different administration schedules.
The rate of cases which discontinued S-1 administration due to
adverse reactions was low in arm A than in arm B and the
cumulative rate of total administration days of S-1 by day 112 (6
months after starting administration) in arm A was higher (69.4%)
than that in arm B (54.4%). Furthermore, the cumulative rate of
relative total administration dose calculated by the rate between
the actual total administration dose and planned total adminis-
tration dose of S-1 was higher in arm A (54.9%) than arm B
(34.3%). The completion rate in patients who received the planned
schedule were not enough; however, the mean of the relative total
administration dose was 76.1% and more than 70% of the patients
could be administered eight courses in arm A. Adverse events were
recorded for 41 patients (82.0%) in arm A and 48 patients (94.1%)
in arm B, most of which were haematological, gastrointestinal and
skin toxicities, as in the phase II study. Most of adverse events in
grade 1 or 2 were controllable. Since S-1 was administered
consecutively, most of the adverse events, such as neutropenia,
diarrhoea and pigmentation, were getting worse gradually. So we
thought that in both arms the rest periods prevented the
aggravation of most adverse events and kept them in low grades.
However, arm B, the longer consecutive administration of S-1
caused the higher incidence and grade of adverse events compared
with arm A. Especially, the incidences of diarrhoea (10 vs 28%;
Po0.05) and skin toxicity (18 vs 37%; Po0.05) were significantly
higher in arm B than in arm A. The 1-year disease-free survival
rates were 81.2% in arm A and 77.0% in arm B, with no statistically
significant difference.
These results suggest that 2-week administration followed by
1-week rest seems to be more tolerable and safer compared to 4-
week administration followed by a 2-week rest. Since higher
incidence and more severe degree of diarrhoea have been found in
Western countries during S-1 administration, the 2-weeks course
holds potential for therapeutic applications. Owing to the short-
term follow-up in the current study, the potential to reduce relapse
after definitive treatments in advanced but curable SCCHN should
be carefully examined in the future. In terms of adjuvant chemo-
therapy, we are planning the phase III comparison study between
S-1 with 2-week administration followed by 1-week rest and daily
UFT administration for 1 year in locoregionally advanced SCCHN.
ACKNOWLEDGEMENTS
We thank the many physicians participating in this trial; Dr S
Fukuda, Hokkaido University, Hokkaido; Dr M Kano, Fukushima
Medical University, Fukushima; Dr S Takahashi, Niigata Uni-
versity, Niigata; Dr T Yoshizumi, Gunma Prefectural Cancer
Center, Gunma; Dr Y Okamoto, Chiba University, Chiba; Dr K
Hayazaki, Chiba Cancer Center, Chiba; Dr S Kishimoto, Tokyo
Medical and Dental University, Tokyo; Dr S Kamata, The Cancer
Institute Hospital, Tokyo; Dr J Ishitoya, Yokohama City University
Medical Center, Kanagawa; Dr K Ohue, Tokai University,
Kanagawa; Dr M Okamoto, Kitazato University, Kanagawa; Dr A
Kubota, Kanagawa Cancer Center, Kanagawa; Dr M Furukawa,
Kanazawa University, Ishikawa; Dr Y Hisa, Kyoto Prefectural
University of Medicine, Kyoto; Dr H Yamane, Osaka City
University, Osaka; Dr K Yoshino, Osaka Medical Center for
Cancer and Cardiovascular Disease, Osaka; Dr K Nibu, Kobe
University, Hyogo; Dr K Yajin, Hiroshima University, Hiroshima;
Dr T Nakajima, Kurume University, Saga; Dr Y Kurono,
Kagoshima University, Kagoshima. We are indebted to Professor
JP Barron of Tokyo Medical University for his review of this
manuscript.
REFERENCES
Akasu T, Moriya Y, Yoshida S, Shirao K, Ohashi Y, Kodaira S, NSAS-CC
Group (2004) Adjuvant oral and tegafur (UFT) improves survival after
complete mesorectal excision (ME) for pathologic TNM stage III rectal
cancer (RC): results of the national surgical adjuvant study (NSAS)-
colorectal cancer (CC) 01 randomized trial. Proc Am Soc Clin Oncol 23:
251 (Abstr. 3524)
Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS,
Rosen FR, Javanovic B, Vokes EE (2004) Competing of death and
second primary tumors in patients with locoregionally advanced head
and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10:
1956–1962
Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F,
Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L,
Weichselbaum RW, Vokes EE (2004) Patterns of failure, prognostic
factors and survival in locoregionally advanced head and neck cancer
treated with concomitant chemoradiotherapy: a 9-year, 337-patient,
multi-institutional experience. Ann Oncol 15: 1179–1186
Cohen EEW, Lingen MW, Vokes EE (2004) The expanding role of systemic
therapy in head and neck cancer. J Clin Oncol 22: 1743–1752
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB,
Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao
KSC, Schultz CJ, Lee N, Fu KK, the Radiation Therapy Oncology Group
9501/Intergroup (2004) Postoperative concurrent radiotherapy and
chemotherapy for high-risk squamous-cell carcinoma of the head and
neck. N Engl J Med 350: 1937–1944
Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL,
Posner MR, Norris Jr CM, Tuttle SA, Schoenfeld DA (1987) An analysis
of induction and adjuvant chemotherapy in the multidisciplinary
treatment of squamous-cell carcinoma of the head and neck. J Clin
Oncol 5: 10–20
Feasible adjuvant therapy administration of S-1 for SCCHN
M Tsukuda et al
888
British Journal of Cancer (2005) 93(8), 884–889 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sForastiere AA, Goepfert H, Maor M, Pajak TK, Weber R, Morrison W,
Glisson B, Trotti A, Ridge JA, Chao C, Perers G, Lee DJ, Leaf A, Ensley J,
Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ
preservation in advanced laryngeal cancer. N Engl J Med 349: 2091–2098
Fujii M, Endo S, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya
J, Ymane H, Fujii H, Honma A, Tomita T (2005) A phase I/II study of S-1
plus cisplatin (CDDP) in patients with head and neck cancer (HNC). Proc
Am Soc Clin Oncol 24: 513 (Abstr. 5552)
Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris
CM, Lake-Willcutt B, Case MA, Costello R, Posner M (2003) Docetaxel,
cisplatin, and 5-fluorouracil-based induction chemotherapy in patients
with locally advanced squamous cell carcinoma of the head and neck.
The Dana Farber Cancer Institute Experience. Cancer 97: 412–418
Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II
study of S-1 in patients with advanced head and neck cancer. Gan To
Kagaku Ryoho 28: 1381–1390
Jacobs C, Makuch R (1990) Efficacy of adjuvant chemotherapy for patients
with resectable head and neck cancer: A subset analysis of the Head and
Neck Contacts Program. J Clin Oncol 8: 838–847
Johnson JT, Wagner RL, Myers EN (1996) A-long term assessment of
adjuvant chemotherapy on outcome of patients with extracapsular
spread of cervical metastases from squamous carcinoma of the head and
neck. Cancer 77: 181–185
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y,
Wada H, Tsuboi M, Hamajima N, Ohta M (2004) A randomized trial of
adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the
lung. N Engl J Med 350: 1713–1721
Kinoshita T, Nakajima T, Ohashi Y, National Surgical Adjuvant Study
Group for Gastric Cancer (N-SAS-GC) (2005) Adjuvant chemotherapy
with uracil-tegafur (UFT) for serosa negative advanced gastric cancer:
results of a randomized trial by national surgical adjuvant study of
gastric cancer. Proc Am Soc Clin Oncol 24: 313 (Abstr. 4021)
Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto
J, Kojima H, Hiratusuka M, Arai K, Sairenji M, Fukushima N, Kimura H,
Nakajima T (2004) Feasibility study of adjuvant chemotherapy with S-1
(TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric
Cancer 7: 104–109
Koizumi W, Kurihara M, Nakano S, Hasegawa K, The S-1 Cooperative
Gastric Cancer Study Group (2000) Phase II study of S-1, a novel oral
derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:
191–197
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999.
CA Cancer J Clin 49: 8–31
Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R,
Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG, Cambell BH (1992)
Adjuvant chemotherapy for respectable squamous cell carcinomas of the
head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol
Phys 23: 705–713
Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E (2002) End points
for new agents in induction chemotherapy for locally advanced head and
neck cancers. Ann Oncol 13: 995–1006
Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-
marketing survey of S-1 in patients with advanced gastric cancer. Gastric
Cancer 8: 6–11
Noguchi S, Koyama H, Uchino J, Uchino J, Abe R, Miura S, Sugimachi K,
Akazawa K, Abe O (2005) Postoperative adjuvant therapy with
tamoxifen, tegafur plus uracil, or both in women with node-negative
breast cancer: a pooled analysis of six randomized controlled trials. J Clin
Oncol 23: 2172–2184
Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi
T, the S-1 Cooperative Colorectal Carcinoma Study Group (2000) Phase
II study of S-1, a novel oral fluoropyrimidine derivative, in patients with
metastatic colorectal carcinoma. Br J Cancer 83: 141–145
Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy
added to locoregional treatment for head and neck squamous cell
carcinoma: three meta-analyses of updated individual data. Lancet 355:
949–955
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998)
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1
(1 MTegafur–0.4 MGimestat–1 M Otastat potassium) in advanced gastric
cancer patients. Eur J Cancer 34: 1715–1720
Schoffski P (2004) The modulated oral fluropyrimidine prodrug S-1, and its
use in gastrointestinal cancer and other solid tumors. Anticancer Dugs
15: 85–106
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H,
Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996a)
Antitumor activity of 1 Mtegafur–0.4 M5-chloro-2,4-dihydoxypyridine–
1 M potassium oxonate (S-1) against human colon carcinoma orthoto-
pically implanted into nude rats. Cancer Res 56: 2602–2606
Shirasaka T, Shimamoto Y, Ohshima H, Yamaguchi M, Kato T, Yonekura
K, Fukushima M (1996b) Development of a novel form of an oral 5-
fluorouracil derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Anticancer Drugs 7: 548–557
Tsukuda M, Ogasawara H, Kaneko S, Komiyama S, Horiuchi M, Inuyama Y,
Uemura T, Uchida M, Kamata S, Okuda M (1994) A prospective
randomized trial of adjuvant chemotherapy with UFT for head and neck
carcinoma. Head and Neck UFT Study Group. Gan To Kagaku Ryoho 21:
1169–11177
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II
study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:
1769–1774
Feasible adjuvant therapy administration of S-1 for SCCHN
M Tsukuda et al
889
British Journal of Cancer (2005) 93(8), 884–889 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s